Curatis Pharma

Executive Summary

Curatis Pharma is a Swiss specialty pharmaceutical company with a dual business model: it distributes third-party orphan drugs in Switzerland while internally developing novel candidates for rare and specialty care diseases. This approach combines stable revenue from established products with upside from its pipeline. The company aims to expand its distribution footprint into major European markets, leveraging its expertise in orphan drug commercialization. Its internal pipeline, though early-stage, targets unmet needs in rare diseases, positioning Curatis for potential high-value approvals.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead pipeline candidate50% success
• Q4 2026Expansion of distribution agreement into new European markets70% success
• H1 2027Potential licensing or partnership deal for proprietary asset40% success